We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo WHX Labs Dubai 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Snibe Diagnostic Presents Immunoassay Systems and Biochemistry Analyzers

By LabMedica International staff writers
Posted on 02 Aug 2018
Image: The Biolumi 8000 integrated system (Photo courtesy of Snibe).
Image: The Biolumi 8000 integrated system (Photo courtesy of Snibe).
Snibe Diagnostic (ShenZhen, China), a leading provider of chemiluminescence immunoassay solutions, presented its range of instruments at the 70th AACC (Annual Scientific Meeting & Clinical Lab Expo), which took place in Chicago, Illinois, USA, from Jul. 29 to Aug. 2, 2018.

Snibe is a professional bio-medical company that specializes in the research, production and sale of clinical laboratory instruments and in vitro diagnostic reagents. It is the first Chinese company to receive FDA clearance for a chemiluminescence immunoassay product. The range of instruments presented by Snibe at this year’s AACC included the Biolumi 8000 integrated system, MAGLUMI 800 and MAGLUMI 2000 chemiluminiscence immunoassay systems and the Biossays 240 biochemistry analyzer.

The Biolumi 8000 integrated system combines an electrolyte module, chemistry module and immunoassay module in a single platform. Tests run on the system provide physicians with a wide range of assays, including 121 immunoassay, 47 chemistry, and four electrolyte assays. The Maglumi 800 chemiluminiscence immunoassay system features three modes of operation, sample loading for up to 40 sample tubes, continuous loading, STAT available, and LIS connection. The system offers a wide test menu, with a throughput of up to 180 tests per hour and the first results available in only 17 minutes. The MAGLUMI 2000 chemiluminiscence immunoassay system has a throughput of up to 180 tests/hour with time to first results of 17 minutes and is always ready-to-use. The Biossays 240 biochemistry analyzer has a throughput of constant 240 tests/hour and allows up to 90 sample positions to be loaded continuously on sample disk with barcode recognition.

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Gold Member
Hybrid Pipette
SWITCH

Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more